Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study)
This study supports the immediate and sustained benefits of initiating ravulizumab in patients with aHUS as seen by the early response and continued improvement in clinical outcomes.
Authors
- Julie Burdeau (ORCID: https://orcid.org/0000-0002-4990-1438)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- Shruti Chaturvedi (ORCID: https://orcid.org/0000-0001-6832-2389)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Ramy Magdy Hanna (ORCID: https://orcid.org/0000-0003-1807-8909)
- Arpita Nag (ORCID: https://orcid.org/0000-0001-5195-3504)
- Yan Wang (ORCID: https://orcid.org/0000-0002-8150-5486)
- Rui Song (ORCID: https://orcid.org/0000-0002-4119-4433)
- Moh‐Lim Ong
Institutions
- Johns Hopkins University (US)
- University of California, Irvine (US)
- AstraZeneca (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1016/j.xkme.2025.101198
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00